Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

The Centers for Disease Control and Prevention’s (CDC) health advisory on the respiratory syncytial virus (RSV) issued Friday brings the focus to a disease that many may not have familiarity ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Respiratory syncytial virus (RSV) causes symptoms similar to the common cold. But in older adults and those with certain medical conditions, the virus can increase the risk of serious illnesses.

Respiratory syncytial virus (RSV) is a common germ that can settle into your lungs and airways. It's the top cause of upper respiratory infection in babies and toddlers, but anyone can get it.

March 3, 2022 / 1:33 PM EST / CBS Boston BOSTON (CBS) -- Help may soon be on the way to protect healthy infants from a common and sometimes life-threatening respiratory virus.

In comparison to previous periods, a larger fraction of the pediatric population hospitalized due to respiratory syncytial virus infections between 2022 and 2023 was two to five years of age (34% ...

Killing on average over 100,000 children across the world per year, respiratory syncytial virus (RSV) is the second greatest cause of death by a single pathogen for children under one year of age ...